Citigroup’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-25,619
| Closed | -$617K | – | 5879 |
|
|
2023
Q1 | $617K | Buy |
25,619
+15,571
| +155% | +$195K | ﹤0.01% | 2963 |
|
|
2022
Q4 | $106K | Buy |
10,048
+6,959
| +225% | +$56.2K | ﹤0.01% | 4001 |
|
|
2022
Q3 | $14K | Sell |
3,089
-3,120
| -50% | -$14.2K | ﹤0.01% | 4891 |
|
|
2022
Q2 | $24K | Sell |
6,209
-5,236
| -46% | -$24.8K | ﹤0.01% | 4904 |
|
|
2022
Q1 | $84K | Sell |
11,445
-7,008
| -38% | -$41.9K | ﹤0.01% | 4504 |
|
|
2021
Q4 | $104K | Sell |
18,453
-34,315
| -65% | -$218K | ﹤0.01% | 4714 |
|
|
2021
Q3 | $338K | Buy |
52,768
+34,394
| +187% | +$221K | ﹤0.01% | 3877 |
|
|
2021
Q2 | $155K | Buy |
18,374
+8,504
| +86% | +$68.6K | ﹤0.01% | 4342 |
|
|
2021
Q1 | $104K | Sell |
9,870
-4,846
| -33% | -$68.2K | ﹤0.01% | 4338 |
|
|
2020
Q4 | $249K | Buy |
14,716
+6,288
| +75% | +$94.3K | ﹤0.01% | 4824 |
|
|
2020
Q3 | $108K | Sell |
8,428
-571,894
| -99% | -$7.22M | ﹤0.01% | 5058 |
|
|
2020
Q2 | $8.19M | Buy |
580,322
+567,271
| +4,347% | +$7.16M | 0.01% | 1460 |
|
|
2020
Q1 | $120K | Buy |
13,051
+9,408
| +258% | +$121K | ﹤0.01% | 5197 |
|
|
2019
Q4 | $54K | Buy |
+3,643
| New | +$32.5K | ﹤0.01% | 6248 |
|
Other funds holding PRVB
Citigroup's PRVB Position: Q2 2023 in Review
Citigroup sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 25,619 shares — an estimated $617K sold.
Citigroup first reported a position in PRVB in Q4 2019 and held it in 14 quarters. The position peaked at $8.19M in Q2 2020. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- Citigroup reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Citigroup sold 25,619 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $617K.
- Citigroup first reported a position in Provention Bio, Inc. Common Stock in Q4 2019 and held it in 14 quarters.
- Citigroup's Provention Bio, Inc. Common Stock position peaked at $8.19M in Q2 2020.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on Citigroup's 13F filing for Q2 2023, filed 10 Aug 2023.